Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex

• Status: Completed
• Trial end date: 2008-01-28
• Target enrollment: 0
• Participant gender: All

Summary

Study aimed to evaluate the efficacy and tolerance of Lazolex®, an emollient gel, to treat mucocutaneous lesions caused by herpes simplex virus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Iveriapharma LLC

Criteria

Inclusion Criteria:

• diagnosis of acute or chronic herpes simplex mucocutaneous infection,

• mild course of disease (defined as body temperature <37.2°C and without signs of general infirmity),

• application of last treatment for herpes simplex infection >3 months,

• available to cooperate during the study,

• provision of written informed consent.

Exclusion Criteria:

• abnormal laboratory results,

• hypersensitivity to the product or its components,

• pregnancy or breastfeeding,

• acute/ chronic renal or liver failure,

• history of migraine,

• organic brain lesion,

• generalized anxiety disorder,

• blood supply disturbance in the vertebrobasilar pool,

• stage 3 essential hypertension,

• concomitant acute or decompensated disease that could affect the study results,

• intake of acyclovir, antibiotics, immunosuppressants, antimetabolites, or glucocorticosteroids during 3-month period prior to the study,

• concomitant participation in another clinical trial.